Skip to Main Content

Paper Details

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.
Nat Med
377
2016
CD8, CD8+, CD8+ T cells, PD-, PDCD1, T cell vaccine, advanced tumors, anti-PD-1, cross-, cross-presenting dendritic cells, cytotoxic T lymphocyte-associated protein (CTLA)-4, immune cells, innate and adaptive immune cells, innate immune cell subsets, melanoma, metastatic cancer, mice, mouse, patients, programmed cell death 1, recombinant interleukin-2, tumor, tumors
Author NameAffiliation
Gregory L SzetoKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT)
Gregory L SzetoRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University
Gregory L SzetoMassachusetts Institute of Technology
Gregory L SzetoKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT)
Gregory L SzetoMassachusetts Institute of Technology
Gregory L SzetoRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University
Jesse M EngreitzMassachusetts Institute of Technology
Jesse M EngreitzThe Broad Institute of MIT and Harvard University
Douglas A LauffenburgerKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT)
Douglas A LauffenburgerMassachusetts Institute of Technology
Douglas A LauffenburgerRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University
Douglas A LauffenburgerKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT)
Douglas A LauffenburgerMassachusetts Institute of Technology
Douglas A LauffenburgerRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University
  • 1 - 14

Datasets

Release 1.2